VOO241004C495000
- 24.00
- 0.000.00%
Vanguard S&P 500 ETF Newsroom
Markets End in the Green; The Dow Hits Record Close.
Weekly Buzz: Market volatility for very good reasons
Global Stocks May Travel up 6% Through 2025 With the U.S. Dodging a Hard Landing: UBS
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
10 Information Technology Stocks Whale Activity In Today's Session
AI Stocks Ripping, Barn Burner Jobs Report - Could Powell Be Wrong?
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Market Clubhouse Morning Memo - October 4th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META And TSLA)
This Is What Whales Are Betting On Apple
Strike Over, Jobs Hot as Soft Landing in Sight | Moovin Stonks
Meta Enters Gen-AI Video Arena With Movie Gen, but Release Date Unknown
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Odds of 50bp Rate Cut in November Plunge After Strong September Payrolls Report
Reaction Roundup: SA Analysts, Experts Weigh in on Jobs Report
Apple Set To Open 4 New Retail Stores In India As Tech Giant Looks To Build On Retail Success
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Market Falls For What Feels Like the Fourth Day | Wall Street Today
Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Apple Analyst Ratings